Cameroon vs Philippines: Average cost of drugs for extensively drug-resistant tuberculosis
Cameroon
227 constant 2022 US$
in 2024
Philippines
282 constant 2022 US$
in 2024
Cameroon rank
54th
Philippines rank
52nd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Cameroon
- Philippines
How they compare
Philippines currently reports 282 constant 2022 US$ against 227 constant 2022 US$ in Cameroon, a difference of 55 constant 2022 US$.
That makes Philippines's figure about 1.2 times Cameroon's.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Philippines ahead.
Cameroon ranks 54th and Philippines ranks 52nd of 56 countries.
Philippines has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cameroon | Philippines | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,251 constant 2022 US$ | 8,943 constant 2022 US$ | 4,693 constant 2022 US$ | Philippines |
| 2020s | 3,004 constant 2022 US$ | 3,710 constant 2022 US$ | 706.75 constant 2022 US$ | Philippines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Cameroon or Philippines?
- Philippines, at 282 constant 2022 US$ against 227 constant 2022 US$ in Cameroon as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Cameroon and Philippines?
- 55 constant 2022 US$, with Philippines ahead.
- How many years of comparable data are there for Cameroon and Philippines?
- 7 years are reported by both, from 2017 to 2024.
- How do Cameroon and Philippines rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Cameroon ranks 54th and Philippines ranks 52nd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.